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We have read with great interest the recent review article by
Sangro et al. published in the Journal of Hepatology [1], which
demonstrated that selective internal radiation therapy (or radio-
embolisation) with yttrium-90-loaded microspheres constitutes
a promising therapeutic approach for the management of hepato-
cellular carcinoma.
The authors judiciously recollect that the concept of radio-
embolization is based on the delivery of a tumoricidal dose to
the tumor, while sparing healthy liver tissue. This point is of par-
amount importance, as the chief active principle of radioemboli-
zation is associated with ionizing radiation, making it necessary
to reach a threshold tumor absorbed dose in order to achieve
good efﬁcacy. As reminded by the author, the absorbed dose
depends on: (i) injected activity; (ii) tumor vessel density; (iii)
arterial ﬂow. These last two features are tumor characteristics
that cannot be modiﬁed, except, possibly, when combining radio-
embolization with the administration of antiangiogenic sub-
stances. However, the injected activity is modiﬁable. It is thus
crucial to be able to retain reliable dosimetry models for thera-
peutic planning.
Sangro et al. claimed that there is no correlation between the
scintigraphic distribution of technetium-99m-labeled macroag-
gregates of albumin (Tc-99m-MAA) and that of microspheres,
and thus there is no reliable dosimetry model. However, this is
only the case for resin microspheres (SIR Sphere, SIRTex Medical
Limited, Sydney, Australia). The study conducted by Knesaureck
et al. [2], which is referenced in the Sangro publication, clearly
showed that only resin microspheres had no correlation. Data
relating to glass microspheres was not provided.
The Milan team [3], revealed a strong correlation between
the tumor-absorbed dose, which is based on Tc-99m-MAA hepa-
tic arterial perfusion scintigraphy, and tumor responses for
treatments using glass microspheres (TheraSphere, MDS Nordi-
on, Ontario, Canada). Therefore, contrary to Sangro’s conclusion,
MAA-based dosimetry appears reliable when using glass micro-
spheres. These results have been conﬁrmed by our research
team [4].
This difference in the prognostic value of Tc-99m-MAA dosim-
etry using either glass microspheres or resin microspheres prior
to performing radioembolisation may be accounted for by funda-
mental differences between the two products.
As highlighted by the authors, the speciﬁc activity of glass
microspheres is 50 times higher than that of resin microspheres
(2500 Bq per sphere vs. 50 Bq per sphere). Consequently, for the
same injected activity, the embolic effect is much higher and
well-recognized with resin microspheres, requiring slow admin-
istration, with repeated angiographic controls for detecting
reﬂow during the procedure. The consequences include an
increased risk of gastric ulcer [5], intrahepatic reﬂux (accidental
injection of total liver during selective injection into the liver lobe
that was not detected on angiography), and reﬂux from the trea-
ted liver area into the non-tumor liver tissue.Journal of Hepatology 2013Therefore, the injection of small amounts of MAA appears to
exhibit a good predictive value of response when using glass
microspheres, which have a low embolic effect, and a poor pre-
dictive value of response when using resin microspheres, which
have a high embolic effect.
It is also important to stress that the maximal activity signif-
icantly differs between the two products, which is crucial from a
radiobiological point of view: 3.2 GBq for resin microspheres vs.
20 GBq for glass microspheres. Previously, we established a mean
tumoral threshold dose of 205 Gy in order to achieve a response
[4]. This threshold dose of 205 Gy enables response prediction
with an accuracy of 91%. In this study, overall survival of patients
having received a tumor dose P205 was signiﬁcantly higher
compared to that of those having received a tumor dose
<205 Gy (18 months [95% CI: 11–1 months] vs. 9 months [95%
CI: 2–31 months], respectively, p = 0.0322) [4]. These ﬁndings
contradict Sangro’s observation stating, ‘‘a cut-off point has not
been yet established’’.
This dose-response concept is of major interest, since the
availability of a reliable predictive model makes it possible to
model the response. In a preliminary study, this approach
resulted in treatment intensiﬁcation in 25% of patients, along
with good tolerance [4]. A study to conﬁrm these ﬁndings is cur-
rently in progress.
From a radiobiological point of view and as recently high-
lighted [6], we conclude that resin and glass microspheres are dif-
ferent products, with probably differing efﬁcacy and toxicity
proﬁles. At present, reliable and predictive dosimetry is possible
when using glass microspheres but not when using resin micro-
spheres. As a result, in the future, using glass microspheres is
likely to be associated with a signiﬁcant improvement in clinical
outcomes, as this tumor dosimetry approach renders the clinical
application of treatment intensiﬁcation possible.vol. 58 j 1053–1061 1055
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Reply to: ‘‘Pre-therapeutic dosimetry evaluation and
selective internal radiation therapy of hepatocellular
carcinoma using yttrium-90-loaded microspheres’’
To the Editor:
We have read with interest the comments made by Garin et al. to
our recently published review on yttrium-90 radioembolization
(RE) for hepatocellular carcinoma (HCC) [1]. Yet, while they raise
relevant questions regarding the dosimetric approach to RE using
yttrium-90 microspheres, they also convey erroneous messages
regarding pretended advantages of glass vs. resin microspheres
that should be clariﬁed.
We never claimed that no correlation exists between the dis-
tribution of radiolabeled macroaggregated albumin (MAA) and
therapeutic microspheres. The referred study by Knesaureck
et al. shows that when such correlation between MAA and resin
microspheres was analyzed, it ranged from high to very poor,
and the average correlation was not the ideal one. A more recent
study by the same group indicates that differences in catheter tip
position are likely to be the main contributor to this mismatch
[2]. No study has been done with glass microspheres so unless
Garin et al. may provide additional data, there is no evidence to
suggest that a better correlation exists for glass microspheres.
In any case, these sorts of data have to be considered cautiously
since the actual distribution of beta radiation cannot be accu-
rately quantiﬁed in vivo after RE.
Furthermore, we made it clear that the MAA scan could be
used to anticipate the average dose of radiation that can be deliv-
ered to tumor areas. The statement made by Garin et al. that MAA
only predicts response when using glass microspheres is
unfounded and it can be misleading for the inexperienced reader.
Several retrospective studies have shown that unsurprisingly, the
average dose received by tumors was higher for those that
showed an objective response after therapy, both for resin [3,4]
and for glass microspheres [5,6]. Nevertheless, a signiﬁcant over-
lap was also observed and a consistent cut-off value has not been
reported. For glass microspheres, proposed thresholds for aimed
tumor absorbed doses range from 205 Gy in the Rennes series
[5] to 500 Gy in the Milano series [6]. According to the manufac-
turer’s instructions, the prescribed activity of glass microspheres
is based on a 2-compartment dosimetry model with the aim of
delivering a radiation dose of 120 Gy to the targeted liver (irre-
spective of the tumor burden). For resin microspheres, users have
to choose between an empiric formula based on body surface
area and tumor burden, or by a 3-compartment dosimetry model
with the aim of delivering a radiation dose of 70–80 Gy to the tar-
geted non-tumoral liver. However, experienced centers have
described different attempts to use other dosimetry models to
improve the efﬁcacy of RE with both resin [7] and glass micro-
spheres [8]. The statement that the dosimetry approach devel-
oped by Garin et al. resulted in treatment intensiﬁcation in 25%
of patients, along with good tolerance has to be taken with cau-
tion since it is based on only 4 patients that received a dose
higher than that prescribed by the conventional method of activ-
ity calculation for glass microspheres [5]. This early experience
from their and other groups with these dosimetry models is cer-
tainly encouraging but only prospective studies in large series of
patients will tell us if this approach proves to preserve safety
while they increase efﬁcacy.
It is well know that with a comparable size range but a differ-
ent activity per sphere, the number of particles used in a typical
RE treatment is higher for resin than for glass microspheres.
Garin et al. invalidly derive from this fact that resin microspheres
are associated with a higher embolic effect and a higher chance of
intrahepatic reﬂux without providing any scientiﬁc support to
these assertions. Furthermore, they sustain that resin micro-
spheres carry an increased risk of gastric ulcer, which again is a
misleading statement. Gastric ulcers result from the unnoticed
presence of collateral vessels and therefore, they are much
dependent on the experience of the interventional radiologist
performing the procedure and on the site of injection. The higher
number of studies reporting gastric ulcers after RE using resin
microspheres is most likely due to the fact that glass micro-
spheres are almost invariably delivered by a selective lobar or
sublobar injection while resin microspheres are quite often
injected into the proper hepatic artery (particularly for unresec-
table liver metastases). When glass microspheres were injected
into the hepatic artery in an early series of HCC patients, 13.6%
of them developed gastric ulcerations [9]. For resin microspheres,
in the study referenced by Garin et al., the Mount Sinai group
reported an incidence of 2.6% among 270 RE-treated patients
[10].
Finally, Garin et al. conclusion that ‘‘resin and glass micro-
spheres are different products, with differing efﬁcacy and toxicity
proﬁles’’ is against all available scientiﬁc evidence. As shown in
Fig. 5 of our review, the overall survival of patients treated with
glass or resin microspheres across the different HCC tumor stages
is very consistent. The incidence of liver-related adverse events
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